Moderna, Merck say their cancer vaccine reduces metastases by 65% in PhII study of high-risk melanoma: #ASCO23
CHICAGO — Moderna’s ambitions to chart a future beyond Covid-19 shots and unleash its mRNA technologies on cancer just got a lot brighter.
The mRNA pioneer and Merck announced new data on Monday at ASCO’s annual meeting for their personalized cancer vaccine — made from mRNA-encoding molecular mugshots unique to an individual’s tumor. In patients who underwent surgery to remove high-risk skin cancer, a combination of the custom shot and Merck’s immunotherapy Keytruda significantly reduced the risk of developing deadly metastases by 65% compared to patients taking Keytruda alone.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.